Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:37:14.063Z.
Calculation as of: 2026-10-06T20:37:14.063Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2023-12-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$259.12M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.14M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.49M
EV/Sales Ratio
1.56x
TTM Avg
1.20x
3Y Avg
2.37x
5Y Avg
5.33x
Market Cap
$259.56M
EV/Sales Ratio
0.99x
TTM Avg
0.74x
3Y Avg
0.47x
5Y Avg
0.82x
Market Cap
$258.63M
EV/Sales Ratio
266.92x
TTM Avg
543.80x
3Y Avg
374.50x
5Y Avg
374.50x
Market Cap
$261.27M
EV/Sales Ratio
9.05x
TTM Avg
17.11x
3Y Avg
33.44x
5Y Avg
33.44x
Market Cap
$261.43M
EV/Sales Ratio
N/A
TTM Avg
8390802.46x
3Y Avg
5153796.41x
5Y Avg
3581310.58x
Market Cap
$256.47M
EV/Sales Ratio
10.47x
TTM Avg
42.40x
3Y Avg
29706.49x
5Y Avg
21359.19x
Market Cap
$255.88M
EV/Sales Ratio
2.00x
TTM Avg
1.60x
3Y Avg
1.66x
5Y Avg
1.91x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $259.12M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 1.56x | 1.20x | 2.37x | 5.33x |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 0.99x | 0.74x | 0.47x | 0.82x |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 266.92x | 543.80x | 374.50x | 374.50x |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 9.05x | 17.11x | 33.44x | 33.44x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | 8390802.46x | 5153796.41x | 3581310.58x |
| AC Immune S.A. (ACIU)vs › | $256.47M | 10.47x | 42.40x | 29706.49x | 21359.19x |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 2.00x | 1.60x | 1.66x | 1.91x |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 5.57x | 5.31x | 6.28x | 18.29x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2023-12-11 | 416.34x |
| 2023-12-08 | 487.44x |
| 2023-12-07 | 554.28x |
| 2023-12-06 | 599.78x |
| 2023-12-05 | 693.16x |
| 2023-12-04 | 685.57x |
| 2023-12-01 | 665.67x |
| 2023-11-30 | 541.00x |
| 2023-11-29 | 530.58x |
| 2023-11-28 | 504.03x |
| 2023-11-27 | 459.48x |
| 2023-11-24 | 473.70x |
| 2023-11-22 | 454.74x |
| 2023-11-21 | 459.95x |
| 2023-11-20 | 475.59x |
| 2023-11-17 | 460.42x |
| 2023-11-16 | 463.74x |
| 2023-11-15 | 459.95x |
| 2023-11-14 | 438.15x |
| 2023-11-13 | 436.72x |
| 2023-11-10 | 449.05x |
| 2023-11-09 | 452.37x |
| 2023-11-08 | 442.41x |
| 2023-11-07 | 433.88x |
| 2023-11-06 | 435.78x |
| 2023-11-03 | 414.45x |
